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Abstract 
Toxins are hazardous biochemical compounds derived from bacteria, fungi, or plants. Some have mechanisms of 
action and physical properties that make them amenable for use as potential warfare agents. Currently, some toxins 
are classified as potential biological weapons, although they have several differences from classic living bio‑terror 
pathogens and some similarities to manmade chemical warfare agents. This review focuses on category A and B 
bio‑terror toxins recognized by the Centers for Disease Control and Prevention: Botulinum neurotoxin, staphylococcal 
enterotoxin B, Clostridium perfringens epsilon toxin, and ricin. Their derivation, pathogenesis, mechanism of action, 
associated clinical signs and symptoms, diagnosis, and treatment are discussed in detail. Given their expected covert 
use, the primary diagnostic challenge in toxin exposure is the early detection of morbidity clusters, apart from back‑
ground morbidity, after a relatively short incubation period. For this reason, it is important that clinicians be familiar 
with the clinical manifestations of toxins and the appropriate methods of management and countermeasures.
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Background
Biological warfare is defined as the intentional use of liv-
ing organisms such as bacteria, viruses and fungi with the 
intent to cause disease, death, or environmental damage 
[1, 2]. Pathogens were classified by the Centers for Dis-
ease Control and Prevention (CDC) into categories A, B 
or C based on ease of transmission, severity of morbidity 
and mortality, and the likelihood of use (see also http://
www.selectagents.gov/SelectAgentsandToxinsList.html 
and https://www.niaid.nih.gov/topics/biodefenserelated/
biodefense/pages/cata.aspx). Category A bio-agents can 
be easily disseminated or transmitted from person to 
person, result in high mortality rates and have the poten-
tial for major public health impact. This might cause 
public panic and social disruption, and require special 
action for public health preparedness. Most of category 
A agents are considered especially dangerous due to 
the potential for airborne transmission. Category B bio-
agents are regarded as moderately easy to disseminate, 
may result in moderate morbidity and low mortality, and 
require diagnostic capacity and enhanced disease surveil-
lance. Category C bio-agents include emerging pathogens 
that could be engineered for mass dissemination because 
of availability, ease of production and dissemination, and 
have the potential for high morbidity and mortality and 
major health impact.
Toxins are harmful proteins derived from living organ-
isms, mainly plants, bacteria, and fungi. Owing to their 
high toxicity, ease of production, and ease of dissemina-
tion, several toxins are regarded as possible bio-terror 
agents [3, 4]. Botulinum neurotoxin is the most potent 
toxin in nature and the only one included in the CDC 
category A [4]. Staphylococcal enterotoxin B, Clostrid-
ium perfringens epsilon toxin, and ricin are included in 
the CDC Category B.
The CDC categorizes natural toxins as biological agents 
even though there is some overlap with man-made 
chemical agents (toxicants). However, natural toxins are 
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usually more toxic than chemical agents, have a longer 
latency period, and they are associated with a lower risk 
of environmental contamination [5, 6]. At the same time, 
there are several important differences between toxins 
and bio-terror pathogens: the morbidity and mortality 
rates are lower with toxins since they are not transmit-
ted from person to person, and they will affect only those 
who were directly exposed to them following dispersion. 
This, together with their relatively short latency period 
compared to live pathogens, shortens the potential dura-
tion of the event. The non-contagious nature of toxins 
also reduces the need for neither healthcare surveillance 
nor using special protective gear by healthcare workers, 
apart from standard precautions. The need for environ-
mental disinfection is minimized as the majority of tox-
ins are sensitive to environmental conditions. Since there 
is no role for prophylactic treatment, there is no need 
in preparing large-scale points for dispensing drugs, as 
opposed to other live bio-terror agents [3, 6, 7].
Toxins cannot be grown in culture or identified by sim-
ple genetic sequencing of amino acids, making detection 
and treatment a more complex challenge. Furthermore, 
poisoning often presents with nonspecific clinical mani-
festations. Therefore, the primary diagnostic challenge 
in toxin exposure is to distinguish clusters of signs and 
symptoms from routine background morbidity. Toxins 
that are airborne tend to cause more severe illness than 
ingested toxins [8]. A high index of clinical suspicion is 
especially important in case of Botulinum neurotoxin 
poisoning; one of the few toxins for which there is an 
available anti-toxin and early administration is life-sav-
ing. In most cases, however, the only available treatment 
is supportive.
The aim of this work is to review the characteristics, 
diagnosis, and treatment of category A and B toxins, 
including Botulinum neurotoxin, staphylococcal entero-
toxin B, Clostridium perfringens epsilon toxin, and ricin, 
in order to raise clinicians’ awareness.
Botulinum neurotoxin
Botulinum neurotoxin (BoNT) is derived from the 
Clostridium botulinum bacterium and causes botulism. It 
is the most potent toxic substance currently known [9].
Exploitation as a bio‑weapon in the past
BoNT was initially used as a biowarfare agent by the Jap-
anese during World War II. Thereafter, it was produced 
by other countries as well, including the USA, USSR, 
and Iraq. In the 1990s, the Japanese cult Aum Shinrikyo 
attempted to launch several terror attacks with BoNT, 
but all of them failed [10, 11]. Given the ease of BoNT 
production, there is a risk of its future use for malicious 
purposes.
Toxin source
Clostridium botulinum is a gram-positive motile rod. 
There are seven serotypes of the bacterium (designated 
A–G) distinguished by the antigenic characteristics of 
the neurotoxins they produce. Serotypes A, B, E, and in 
rare cases, F have been described as causing disease in 
humans [9].
Pathogenesis
Natural BoNT poisoning usually occurs by ingestion of 
formed toxin as a result of inappropriate preparation and 
preservation of certain food items (food-borne botu-
lism), or sometimes by spores germinating and produc-
ing the toxin in the immature intestinal tract of infants 
(infant botulism). Natural poisoning can also occur as a 
consequence of bacterial overgrowth in necrotic wounds 
(wound botulism) or in individuals with a gastrointestinal 
disease (adult colonization botulism). Inhalational expo-
sure to BoNT aerosol is regarded as a possible bio-terror 
threat. In any case, the disease develops within 12–36 h 
from the moment the toxin enters the body, regardless of 
the route of exposure [9, 12].
Mechanism of action and resistance
BoNT is active in the neuromuscular junctions of the 
peripheral nervous system. It acts by blocking acetylcho-
line release from the presynaptic nerve endings, causing 
weakness and paralysis of the corresponding muscles. 
The interference with synaptic activity is prolonged 
owing to the long half-life of the toxin [10]. The toxin can 
be inactivated in a temperature of 85  °C for a period of 
5 min, by exposure to the sun for 1–3 h, or by using chlo-
rine solutions [13].
Clinical manifestations
All forms of botulism lead to the same clinical syndrome 
of symmetrical cranial neuropathy, including diplopia, 
ptosis, dysphagia, xerostomia, dysphonia, or dysphasia, 
in combination with symmetrical descending paralysis. In 
most cases, there is no fever. Occasionally, gastrointestinal 
symptoms, such as abdominal pain, nausea, vomiting, or 
diarrhea, may precede the neurological presentation. The 
paralysis may progress to include the respiratory muscles 
with subsequent respiratory failure [9, 12].
Diagnosis
The clinical diagnosis of botulism is based mainly on 
medical history and physical examination. In naturally-
occurring botulism, the bacteria can be isolated from 
stool, blood, or food samples. In a bio-terror scenario, 
when individuals are exposed to an aerosolized toxin, tra-
ditional microbiological tests are not helpful. Gene detec-
tion methods are an option if the offending substance 
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contains bacterial residue. The gold-standard diagnostic 
test is the indirect mouse neutralization bioassay (see 
Ref. [14] for details). The main disadvantage of this test is 
its 96-h duration and lack of sufficient sensitivity. A new 
method of endopeptidase-mass spectrometry is gain-
ing credibility as a promising method that addresses the 
limitations of the mouse assay [15–19]. Electromyogra-
phy can strongly support the clinical diagnosis showing 
a typical pattern for botulism. Findings on routine blood 
tests and brain imaging are usually normal, but may serve 
to rule out other diagnoses [9, 12, 13].
Treatment
Treatment of botulism is mainly supportive, including 
prolonged mechanical ventilation. An equine-derived 
anti-toxin has been produced which inhibits the free 
toxin from binding to nerve endings, thereby preventing 
paralysis and respiratory insufficiency. Its efficacy dimin-
ishes once clinical signs develop, thus treatment should 
be administered immediately on grounds of clinical sus-
picion, prior to definite laboratory diagnosis. The anti-
toxin is administered only in a hospital setting because 
of the risk of anaphylactic reaction. However, with the 
recent introduction of a product consisting only of the 
F(ab)2 segment of the antibody, anaphylaxis has become 
rare [12, 13, 20].
Prevention
In the past, an active vaccine containing formalin-treated 
toxin was administered to laboratory personnel at risk of 
coming into contact with the toxin. The CDC has since 
discontinued this practice [21].
Staphylococcal enterotoxin B
Staphylococcal enterotoxin B (SEB) is produced by the 
Staphylococcus aureus bacterium [22]. It is the only toxin 
of S. aureus that is classified as a bio-terror agent.
Exploitation as a bio‑terror agent
Inhalational exposure to SEB is extremely rare, and 
any event should immediately raise suspicions of mali-
cious intent [23]. A series of laboratory accidents in 
the 1940s–1960s in the United States led to intensive 
research of the toxin which yielded a vast amount of per-
tinent information [24].
Toxin source
Staphylococcus aureus is a gram-positive bacterium 
which does not produce spores and can survive in both 
aerobic and anaerobic conditions. It exists in nature on 
the skin and mucosa of humans and animals and can 
be found among the normal respiratory tract flora of 
25–50 % of the population [25–27].
Pathogenesis
SEB poisoning occurs mainly by consumption of con-
taminated food or water, and is considered a bioterror 
threat mainly due to the potential for an intentional use 
in food poisoning scenarios. Other routes of entry are the 
respiratory tract, the vaginal tract (via infection of a vagi-
nal tampon, leading to the “toxic shock syndrome”), and 
the eyes (causing conjunctivitis). SEB is toxic in relatively 
minute doses [28]. It is not transmitted from person to 
person by contact or through air [22].
Mechanism of action and resistance
SEB has several advantages as a bio-warfare agent, 
including its solubility in water, relatively high resist-
ance to heat (it remains active even after a few minutes in 
boiling water) and to acidic pH levels and it is easily dis-
persed in air. The protein has a unique structure to sus-
tain intestinal proteases [22, 25–27, 29]. The mechanism 
by which it exerts its intestinal injury is not fully clear. 
In the case of toxic shock syndrome it brings to a non-
specific activation of T cell lymphocytes, bypassing the 
specific interaction between T-cell receptors and major 
histocompatibility complex molecules, which results in a 
cytokine storm [22, 27, 30].
Clinical manifestations
The symptoms of SEB poisoning depend on the route 
of exposure. The toxin is most dangerous when inhaled, 
causing hyperpyrexia within 3–12 h of exposure in addi-
tion to cough, rigor, headache, and myalgia. The fever 
may last for 2–5  days, and the cough up to 4  weeks. 
Inhalation of high doses may lead to acute respiratory 
distress syndrome (ARDS), and trigger shock and multi-
organ failure [22–24, 26, 31–33]. Ingestion of SEB leads 
to nausea, vomiting, diarrhea, and abdominal cramps, 
which appear within 1–8 h of exposure, without fever or 
respiratory symptoms. Symptoms usually resolve within 
24–48 h [22, 24, 25, 27, 31–34].
Diagnosis
SEB can be detected by immunological assays in blood, 
urine, or sputum [35] up to 12–24 h from exposure; after 
that, it is undetectable in body fluids [24, 27]. In solid or 
liquid food products, SEB is detectable even in minute 
concentrations. Occasionally, polymerase chain reaction 
(PCR) is useful for detecting residual bacterial DNA in 
water, food, or clinical samples. Serology is usually bene-
ficial only for retrospective detection of the toxin [36, 37].
Treatment and prevention
Treatment is mainly supportive and does not require 
antibiotics. Currently, there is no available antidote or 
preventive vaccine, although there are several ongoing 
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attempts at vaccine development, still in preliminary 
stages [34, 38–40].
Clostridium perfringens epsilon toxin
The Clostridium perfringens Epsilon toxin (ETX) is the 
third most potent toxin in nature following BoNT and 
the tetanus toxins [31, 41]. The toxin is produced by 
the gram-positive, rod-shaped spore-forming anaero-
bic bacterium Clostridium perfringens type B and D, 
and impacts usually ruminants, especially young sheep, 
where it can cause a highly lethal enterotoxemia [41, 42].
Exploitation as a bio‑terror agent
The existing literature does not suggest that human poi-
soning by ETX naturally occurs even infrequently [43]. 
ETX is considered as a potential bioterrorism agent due 
to its high potency, and has been classified as a category 
B agent by the CDC [31, 41, 44]. Possible exposure route 
in case of a bioterror attack include aerosol, and food- 
and waterborne exposures [45].
Toxin source
The natural habitat of the toxin-producing bacterium is 
the environment, and it can be found in soil, dust, sedi-
ment, litter, cadavers, and even in the digestive tract of 
healthy animals though in low numbers [42]. Only few 
ETX-mediated natural diseases have been reported in 
man [31, 42].
Pathogenesis
Following rapid growth of the bacterium, such as in the 
intestines of young animals in which the resident diges-
tive tract microflora is not yet developed or functional, 
or in cases of overeating a rich diet high in cereal crops 
leading to a passage of undigested fermentable carbohy-
drates, high production of ETX may occur, followed by 
enterotoxemia and injury to other target organs [42].
Mechanism of action and resistance
ETX is produced in the exponential growth phase of the 
bacterium as a prototoxin. It is then converted by spe-
cific proteases to an active ETX in the intestines [41, 46]. 
ETX is a pore-forming toxin that increases cell perme-
ability to small molecules and ions [31, 41]. The toxin acts 
locally in the intestines, increases the permeability of the 
gut mucosa, and then passes through and disseminates 
through the circulation to other organs, causing micro-
vascular endothelial lesions mainly in the brain, the lungs 
and the kidneys, leading to toxic shock and death [41, 42, 
46, 47]. In the kidneys it will cause interstitial hemor-
rhage with edema and degeneration of tubular epithelium 
[42, 44]. In the brain it alters the integrity of the blood–
brain-barrier, causing bilateral symmetrical lesions in 
several brain areas consisting of perivascular edema [42, 
48], resulting in foci of hemorrhage and necrosis and 
leading to neuronal damage [41, 42, 49]. ETX also has a 
direct and rapid effect in brain through targeting specific 
glutamatergic neurons, stimulating glutamate release 
and inducing neuronal cell damage [50, 51]. Once aero-
solized, the toxin is stable in environmental conditions 
for a period of 8 h, and exposure to even a minute dose of 
1 µg/kg may be fatal [45].
Clinical manifestations
There are no available reports examining the effects of 
ETX on humans besides two case reports in humans 
published in the 1950s [31, 41]. However, it is evident 
that the toxin imposes risk to humans, either in natural 
conditions or in a bioterror setting through mass dis-
semination via aerosol [41, 44]. In the lack of reliable 
or established human data, it is assumed that there is a 
latent period lasting for 1–12  h between exposure and 
the appearance of clinical signs and symptoms. Inhala-
tion of the toxin may result in vascular endothelial cell 
damage in the lungs, leading to pulmonary edema. From 
the lungs, the toxin will be spread to other organs, with 
renal, cardiovascular and central nervous system injuries, 
resulting in brain edema, altered consciousness, seizures, 
and within several hours, death will ensue [41, 44, 45].
Diagnosis
Since introducing non-animal alternatives, the classic 
mouse assay involving toxin neutralization with C. per-
fringens type-specific antisera is less in use. Use of ELISA 
technology for specifically detecting ETX in intestinal 
contents is one of the best ways to confirm poisoning 
[52]. Quantitation of ETX protein is also possible using a 
novel, mass spectrometry technique [43, 53]. Mass spec-
trometry avoids cross-reactivity issues intrinsic in any 
antibody-based assay; however, ELISA and mass spec-
trometry do not determine whether the detected protein 
is biologically active. A latex agglutination test has been 
developed and a cytotoxicity assay using Madin–Darby 
canine kidney (MDCK) cells has been published [54]. 
PCR assays can identify the epsilon toxin gene, if it is pre-
sent [43]. In the first stages of the disease, laboratory tests 
may show hemolytic anemia, thrombocytopenia, hypox-
emia, and elevated liver enzymes. In later stages, pancy-
topenia is evident [45].
Treatment and prevention
The mainstay of medical treatment is supportive care. 
Currently, there is a formalin-inactivated vaccine and 
an equine-derived antitoxin approved for animal use 
only. The high lethality and the rapid onset of clinical 
manifestations limit their efficacy [41, 55, 56]. Specific 
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high-affinity toxin antagonists being investigated include 
monoclonal antibodies and selected oligonucleotides 
(aptamers) and dendrimer-based polymers [41, 42, 57]. 
Caregivers should use standard precaution measures 
when treating ETX casualties.
Ricin
Ricin is produced from the Ricinus communis plant 
which is found worldwide.
Exploitation as a bio‑terror agent
Ricin was investigated as a bio-warfare agent in the 1940s 
in the USA and was used in the assassination of the Bul-
garian journalist Georgi Markov in 1978. Ricin may 
also have been used in the Iran-Iraq war in the 1980s. 
Recently, envelopes containing ricin powder were sent by 
terror organizations to government personnel in Great 
Britain and in the USA [58–60].
Pathogenesis
Ricin can be produced in liquid or solid forms (as a pow-
der). It can be injected or disseminated via food, water, 
or air [61, 62]. All routes of exposure except ingestion are 
usually intentional, but human-to-human transmission 
does not occur [60]. Ricin is highly toxic, especially when 
inhaled, but it is considered less potent than other toxins 
[5, 59].
Mechanism of action and resistance
Ricin penetrates the cells by binding to cell membrane 
receptors. It acts by inhibiting protein synthesis at the 
level of the ribosome [6]. Ricin is stable in environmental 
conditions. It can be inactivated in a temperature of 80 °C 
for a period of 10 min or at 50 °C for a period of 1 h, and 
by using chlorine solutions [5].
Clinical manifestations
The clinical presentation of ricin poisoning depends on 
the dosage and route of exposure. Symptoms of inhala-
tional exposure appear within 4–8 h and are nonspecific, 
including fever, cough, dyspnea, nausea, diaphoresis, and 
arthralgia. Studies in animals exposed to inhalational 
ricin reported such pathophysiological changes as necro-
sis and pulmonary edema leading to death from ARDS 
and respiratory failure within 36–72  h [63]. Respiratory 
symptoms do not occur in other routes of exposure, 
although pulmonary edema may develop due to capillary 
leak syndrome.
Intramuscular injection of ricin leads to local mus-
cle necrosis and regional lymphadenopathy with mini-
mal involvement of internal organs. Following ingestion 
of ricin, the clinical manifestations include: nausea and 
vomiting, diarrhea, hypotension, hematuria, and renal 
failure. Further tests reveal necrosis of intestinal epithe-
lial cells, hemorrhage, and necrosis of the liver, spleen 
and kidneys. Some patients have hallucinations, seizures, 
and life-threatening multi-organ failure. Findings on 
blood and urine analysis are nonspecific: elevated levels 
of transaminases, lactate dehydrogenase and bilirubin, 
leukocytosis, metabolic acidosis, hypoglycemia or hyper-
glycemia, increased creatine kinase, and proteinuria. 
There may also be electrocardiogram changes.
Exposure to ricin via direct contact of skin or mucous 
membranes is not typical and may lead to erythema and 
pain [5, 59–61].
Diagnosis
Clinical suspicion of inhalational exposure to ricin is 
based on the appearance of severe respiratory illness in 
a cluster of otherwise healthy individuals with a com-
mon epidemiological background. The diagnosis is made 
by immunoassays of clinical samples taken from nasal 
mucosa, skin or blood, or environmental samples taken 
from the point of dispersion. Serology is useful only 
for retrospective documentation. Occasionally, Rici-
nus communis plant DNA can be detected in products 
containing ricin [59, 60]. Urine can be tested for rici-
nine level within 2  days after exposure, since ricinine 
and ricin originate from the same source [62]. Studies 
have recently suggested the use of nanopores covered 
with short single-stranded DNA or RNA molecules, 
called aptamers, which bind to pre-selected targets with 
high affinity and specificity [64]. This novel method has 
shown high potential as both a diagnostic and a thera-
peutic tool [64].
Treatment
Even before referral to the hospital, patients exposed 
to ricin powder should be immediately undressed and 
washed with soap and water. In the event of blurred 
vision or direct contact with the eyes, the eyes should 
be rinsed with water [60]. In-hospital treatment consists 
of rehydration, restoration to normal electrolyte levels, 
and respiratory support if needed. Gastric lavage or acti-
vated charcoal have not proven effective but can be used 
in the first hour after oral poisoning [59, 61]. Dialysis is 
not effective. Specific anti-toxin is currently in advanced 
developmental stages [59, 61].
Prevention
Active vaccinations based on toxoid or mutant toxin are 
being developed. One of these is RiVax, based on a deriv-
ative of the toxin’s subunit-A chain that is enzymatically 
inactive and lacks the residual toxicity of the holotoxin. 
Animal models show it has a high efficacy and a good 
safety profile in humans [59, 61, 65].
Page 6 of 7Berger et al. Disaster and Mil Med  (2016) 2:7 
Conclusions
Toxins are a unique subgroup of bio-threat pathogens. 
BoNT, SEB, ETX, and ricin are considered by the CDC 
to be potential bioterror agents owing to their short 
incubation period and high toxicity. This review high-
lights important characteristics of these toxins in this 
context, as distinct from living pathogens and chemi-
cal warfare agents. These differences require different 
means of preparedness, diagnosis, treatment, contain-
ment, and prevention. A finding of a cluster of previously 
healthy individuals with severe respiratory symptoms 
in the absence of a known causative agent and in the 
appropriate epidemiological setting should raise clini-
cal suspicions of exposure to a toxin. Clinicians need to 
be familiar with the unique features of toxins and their 
clinical manifestations in order to administer supportive 
care or specific treatments as soon as possible to prevent 
clinical deterioration and contain outbreaks.
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